Healthcare Providers and Services
Company Overview of Progyny, Inc.
Progyny, Inc. operates as a healthcare company that provides fertility services to consumers, employers, and health plans. It offers a non-invasive time-lapse imaging system to aid in the early embryo selection; a no-restriction IVF package plan for patients; egg freezing options through its network of fertility doctors across the United States; and a patient-matching technology platform for the fertility industry. Progyny, Inc. has a strategic alliance with Mercer L.L.C. Progyny, Inc. was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in April 2015. The company was incorporated in 2008 and is based in New York, New York with operations in San Francisco and Menlo Park,...
99 Hudson Street
New York, NY 10013
Founded in 2008
Key Executives for Progyny, Inc.
Chief Financial Officer and Chief Operating Officer
President of Healthcare Services
Senior Vice President of Clinical Affairs
Compensation as of Fiscal Year 2016.
Progyny, Inc. Key Developments
Progyny, Inc. Announces Appointment of Peter Anevski as Chief Financial Officer and Chief Operating Officer
Jan 9 17
Progyny announced that the appointment of former WebMD CFO, Peter Anevski, as its Chief Financial Officer and Chief Operating Officer. Pete brings over 17 years of experience in the healthcare industry at WebMD.
Progyny, Inc. Announces Management Appointments
Dec 16 16
Progyny named former WebMD head David Schlanger as its new CEO. Progyny also announced the appointment of Norman C. Payson, M.D. to its board of directors. David Schlanger has been a healthcare executive for more than 25 years and most recently was the CEO of WebMD from 2013 to 2016. During his tenure leading WebMD, the company achieved record levels of revenue and profitability, saw WebMD's and Medscape's audiences grow to record highs and maintained their positions as the industry leaders in providing health information and digital services to health care professionals, consumers, and corporate employees. Prior to his time as CEO, Schlanger held various other senior positions at WebMD, including leading the strategy, M&A and business development functions. Payson is currently the chairman of the board of trustees for the City of Hope, and board member of Evolent Health, Inc. and Apria Healthcare Group, Inc. He has more than 30 years of experience as a chief executive officer for multiple healthcare organizations and is well known for his knowledge on engaging physicians and hospitals in their participation in health plans.
Progyny Announces New Study That Will Further Aid Embryo Screening with the Use of Progyny’s Eeva™ Test for in Vitro Fertilization Patients
Jul 12 16
Progyny announced a new study that will further aid embryo screening with the use of Progyny’s Eeva™ (early embryo viability assessment) Test for in vitro fertilization (IVF) patients. The study was presented at the European Society of Human Reproduction and Embryology’s (ESHRE) annual conference in Helsinki, Finland. The study focused on identifying specific markers of chromosomally normal blastocysts to determine which chromosomally normal embryos implanted and led to a live birth versus similar embryos that did not lead to a live birth. These markers were identified using the Eeva Test, the only FDA cleared, non-invasive early embryo screening tool. This analysis lays a foundation to further assist embryologists with determining a patient’s embryo transfer order. The study was designed to further enhance the performance of current embryo screening techniques to better understand which chromosomally normal embryos are likely to lead to a live birth. The study analyzed 55 patients with 81 transferred euploid blastocysts from fresh and frozen cycles from 2012 to 2013. Out of the 81 blastocysts transferred, 43 led to a live birth. Eeva’s Time Lapse System automatically processed embryo markers looking at dynamic blastocyst development including the number, frequency, timing and rate of collapses during embryo culture. The study determined that euploid blastocysts with more frequent and longer blastocyst collapse events have a lower live birth rate when compared to similar embryos that implanted and led to a live birth. This dynamic blastocyst marker, termed High Collapse Index by the authors, may compromise embryo viability or may be a new mark of embryo quality.
Similar Private Companies By Industry
Recent Private Companies Transactions
June 15, 2016